weight gain after stopping glp-1 medication GLP-1s: Regain and Maintenance Tips weight gain after stopping glp-1

La bassa incidenza riportata nei trial precedenti riflette probabilmente una sottostima legata allassenza di questa voce nei moduli di raccolta dati originali, corretta solo dopo i segnali emersi in corso di studio

Boxed Warning (Thyroid C-Cell Tumor Risk) GLP-1 receptor agonists, including semaglutide, carry an FDA boxed warning regarding the potential risk of thyroid C-cell tumors

Common adverse effects , particularly during dose escalation, include: Nausea (reported by 2050% of patients, usually mild to moderate) Vomiting, diarrhoea, or constipation Abdominal discomfort or bloating Reduced appetite (therapeutic effect, but may feel unusual initially) Fatigue or headache These effects typically diminish over several weeks as tolerance develops

However, most people begin to feel a noticeable improvement in gastrointestinal symptoms within 7 to 10 days after their last injection

Obesity in PCOS women exacerbates these metabolic disturbances and aggravates its symptoms